186 related articles for article (PubMed ID: 36499557)
1. Peptide Modification Diminishes HLA Class II-restricted CD4
Doonan BP; Amria S; Bethard JR; Banik NL; Hathaway-Schrader JD; Haque A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499557
[TBL] [Abstract][Full Text] [Related]
2. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.
Goldstein OG; Hajiaghamohseni LM; Amria S; Sundaram K; Reddy SV; Haque A
Cancer Immunol Immunother; 2008 Oct; 57(10):1461-70. PubMed ID: 18343923
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.
Doonan BP; Haque A
J Clin Cell Immunol; 2015 Aug; 6(4):. PubMed ID: 26807308
[TBL] [Abstract][Full Text] [Related]
4. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY
Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111
[TBL] [Abstract][Full Text] [Related]
5. HLA class II antigen presentation by prostate cancer cells.
Younger AR; Amria S; Jeffrey WA; Mahdy AE; Goldstein OG; Norris JS; Haque A
Prostate Cancer Prostatic Dis; 2008; 11(4):334-41. PubMed ID: 17938645
[TBL] [Abstract][Full Text] [Related]
6. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
Kobayashi H; Nagato T; Oikawa K; Sato K; Kimura S; Aoki N; Omiya R; Tateno M; Celis E
Clin Cancer Res; 2005 May; 11(10):3869-78. PubMed ID: 15897588
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
8. GILT in Thymic Epithelial Cells Facilitates Central CD4 T Cell Tolerance to a Tissue-Restricted, Melanoma-Associated Self-Antigen.
Rausch MP; Meador LR; Metzger TC; Li H; Qiu S; Anderson MS; Hastings KT
J Immunol; 2020 Jun; 204(11):2877-2886. PubMed ID: 32269095
[TBL] [Abstract][Full Text] [Related]
9. HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy.
Doonan BP; Haque A
Open Cancer Immunol J; 2010 Jan; 3():1-7. PubMed ID: 24163711
[TBL] [Abstract][Full Text] [Related]
10. GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.
Hathaway-Schrader JD; Norton D; Hastings K; Doonan BP; Fritz ST; Bethard JR; Blum JS; Haque A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162988
[TBL] [Abstract][Full Text] [Related]
11. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
12. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
[TBL] [Abstract][Full Text] [Related]
13. Functional requirements for the lysosomal thiol reductase GILT in MHC class II-restricted antigen processing.
Hastings KT; Lackman RL; Cresswell P
J Immunol; 2006 Dec; 177(12):8569-77. PubMed ID: 17142755
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis.
Zhao D; Hajiaghamohseni LM; Liu X; Szulc ZM; Bai A; Bielawska A; Norris JS; Reddy SV; Hannun YA; Haque A
Cytokine; 2020 Nov; 135():155219. PubMed ID: 32738771
[TBL] [Abstract][Full Text] [Related]
16. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
19. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
Zelba H; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Seibold M; Harter J; Latzer P; Hadaschik D; Battke F; Golf A; Rettig MB; Biskup S
Front Immunol; 2023; 14():1271449. PubMed ID: 37920460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
